Quality Measure Implementation Guide

This page is part of the Quality Measure STU2 for FHIR R4 Implementation Guide (v0.1.0: STU 1 Ballot 1) based on FHIR R3. The current version which supercedes this version is 3.0.0. For a full list of available versions, see the Directory of published versions

Measure-measure-exm125-FHIR

Formats: XML, JSON, Turtle

Id: Measure/measure-exm125-FHIR
Type:
system: http://hl7.org/fhir/measure-type
code: process
Identifier: system: http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/cms
value: 146
system: http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/nqf
value: 0002
Title: Breast Cancer Screening
Status: active
Description: Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer
Purpose: Women 51-74 years of age with a visit during the measurement period
Use Context:

code: program

value:
text: eligibile-provider

Topic:
system: http://loinc.org
code: 57024-2
display: Health Quality Measure Document
Contributor: author: National Committee for Quality Assurance
Related:

type: citation

citation:
American Cancer Society. 2010. Cancer Facts & Figures 2010. Atlanta: American Cancer Society.

type: citation

citation:
National Cancer Institute. 2010. "Breast Cancer Screening." http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional

type: citation

citation:
National Business Group on Health. 2011. Pathways to Managing Cancer in the Workplace. Washington: National Business Group on Health.

type: citation

citation:
U.S. Preventive Services Task Force (USPSTF). 2009. 1) "Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement." 2) "December 2009 addendum." Ann Intern Med 151(10):716-726.

type: citation

citation:
BreastCancer.org. 2012. U.S. Breast Cancer Statistics. www.breastcancer.org/symptoms/understand_bc/statistics.jsp

Library:

reference: Library/library-exm125-FHIR

Disclaimer: The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
Scoring:
system: http://hl7.org/fhir/measure-scoring
code: proportion
Rationale: Breast cancer is one of the most common types of cancers, accounting for a quarter of all new cancer diagnoses for women in the U.S. (BreastCancer.Org, 2011). It ranks as the second leading cause of cancer-related mortality in women, accounting for nearly 40,000 estimated deaths in 2013 (American Cancer Society, 2011). <br> According to the National Cancer Institute's Surveillance Epidemiology and End Results program, the chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 30, it is one in 2,212. By age 40, the chances increase to one in 235, by age 50, it becomes one in 54, and, by age 60, it is one in 25. From 2004 to 2008, the median age at the time of breast cancer diagnosis was 61 years among adult women (Tangka et al, 2010). <br> In the U.S., costs associated with a diagnosis of breast cancer range from $451 to $2,520, factoring in continued testing, multiple office visits, and varying procedures. The total costs related to breast cancer add up to nearly $7 billion per year in the U.S., including $2 billion spent on late-stage treatment (Lavigne et al, 2008; Boykoff et al, 2009).
Clinical Recommendation: The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 50-74 years (B recommendation). The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms (C recommendation). The Task Force concludes the evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years and older (I statement). <br> U.S. Preventive Services Task Force (2009) <br> Grade: B recommendation. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. <br> Grade: C recommendation. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. <br> Grade: D recommendation. The USPSTF recommends against teaching breast self-examination (BSE). <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer.
Guidance: Patient self-report for procedures as well as diagnostic studies should be recorded in 'Procedure, Performed' template or 'Diagnostic Study, Performed' template in QRDA-1. Patient self-report is not allowed for laboratory tests. <br> This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, MRIs or tomosynthesis (3D mammography), because they are not appropriate methods for primary breast cancer screening.
Group:

Identifier:
value: group-1

Population:

Identifier:
value: initial-population-identifier

criteria: Initial Population

Identifier:
value: numerator-identifier

criteria: Numerator

Identifier:
value: denominator-identifier

criteria: Denominator

Identifier:
value: denominator-exclusions-identifier

criteria: Denominator Exclusion

Supplemental Data:

Identifier:
value: sde-ethnicity

usage:
system: http://hl7.org/fhir/measure-data-usage
code: supplemental-data

criteria: SDE Ethnicity

Identifier:
value: sde-payer

usage:
system: http://hl7.org/fhir/measure-data-usage
code: supplemental-data

criteria: SDE Payer

Identifier:
value: sde-race

usage:
system: http://hl7.org/fhir/measure-data-usage
code: supplemental-data

criteria: SDE Race

Identifier:
value: sde-sex

usage:
system: http://hl7.org/fhir/measure-data-usage
code: supplemental-data

criteria: SDE Sex